This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Just the Facts, Ma'am: July Strategy Update
by John Blank
Summer picks for the taking.
Forget Big Tech, Biotech ETFs are Soaring Higher
by Neena Mishra
Biotech stocks are surging of late; we discuss the reasons behind the rebound and highlight the best performing ETFs.
How Kite Pharma Is Revolutionizing the Fight Against Cancer
by Eric Dutram
Immunotherapy is a hot corner of the biotech world. Learn how companies in this sector fight cancer in this podcast which features Dr. David Chang, the Chief Medical Officer of Kite Pharma. Do not miss it!
5 Reasons Why Biotech ETFs are Soaring
by Sanghamitra Saha
Reasons that propelled the biotech space and the related ETFs higher.
4 Stocks & ETFs to Buy on Clovis' Positive Drug Data
by Sanghamitra Saha
Clovis Oncology clinical trial data has given a boost to the biotech sector and put these stocks and ETFs in focus.
Fresh Capital to Be Injected into Biotech Stocks: 5 Must-Buys
by Tirthankar Chakraborty
IBB surged 17% since Trump's win but is still down 23% from its all-time intraday high scaled in the July of 2015.
The Latest Market Trends Every Biopharma Investor Needs to Know
by Ryan McQueeney
Speaking at MedCity INVEST, a national healthcare investing conference in Chicago hosted by MedCity News, Jonathan Norris of Silicon Valley Bank, alongside Ryan Jalowiecki from PwC, highlighted the latest trends in the public healthcare markets. If you are a serious biopharma investor, you won't want to miss this.
Stocks to Watch Ahead of GOP Healthcare Vote
by Ryan McQueeney
Lawmakers are scheduled to vote on the GOP's repeal-and-replace healthcare bill this afternoon. Here are some major stocks to watch as investors react to the vote.
Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus
by Zacks Equity Research
Gilead beat Zacks EPS estimates, but missed on revenue, in the first quarter of 2017.
Zacks Podcast Highlights: Should Investors Forget the Obamacare Battle and Focus on HealthTech Stocks Instead?
by Eric Dutram
Although changes might be coming to the world of health care, this industry could be the spot for investors to focus on regardless of what Washington decides.
Health Care and Technology: A Perfect Combo for Stock Investors Now?
by Eric Dutram
Although changes might be coming to the world of health care, this industry could be the spot for investors to focus on regardless of what Washington decides.
Are Q1 ETF Toppers Healthy Enough for Further Run in Q2?
by Sanghamitra Saha
Let's do a health check-up for top performing ETFs of Q1 and find out if these can succeed in Q2 too.
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
Biotech Bull Making a Comeback
by Kevin Cook
A triple-bottom at $240 was bolstered by the headline capitulation of an infamous Valeant investor
Time to Buy Biotech ETFs?
by Zacks Equity Research
After a painful 2016, biotech stocks are recovering this year. What lies ahead?
Healthcare ETFs in Focus on Obamacare Replacement Plan
by Sweta Killa
House Republicans have released the long-awaited bill to repeal and replace Obama's signature healthcare law last evening. This will unwind much of the law over the next three years.
Trump's Immigration Plans an Overhang on Biotech ETFs?
by Zacks Equity Research
Immigration related uncertainty has put biotech ETFs in focus.
ETF Industry to Get a Product on Marijuana?
by Sanghamitra Saha
A new fund has been filed targeting the medical marijuana industry.
Biotech ETFs Powered by Q4 Earnings
by Sweta Killa
Improved earnings are driving the biotech space and ETFs higher over the past 10 days.
Zacks Market Edge Highlights: Health Care SPDR ETF, iShares NASDAQ Biotechnology ETF, Acadia, Aetna and Gilead
by Zacks Equity Research
Zacks Market Edge Highlights: Health Care SPDR ETF, iShares NASDAQ Biotechnology ETF, Acadia, Aetna and Gilead
Healthcare Stocks: The Buying Opportunity of the Year?
by Tracey Ryniec
Tracey and Kevin discuss whether healthcare stocks are still the ???sure things??? they???ve been the last 10 years.
Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting
by Madeleine Johnson
Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.
What Lies Ahead for Biotech ETFs in Trump Era?
by Zacks Equity Research
Despite political risks, there are many factors supporting growth in the biotech sector.
4 Top Biotech Mutual Funds for 2017
by Zacks Equity Research
Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance
Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment
by Madeleine Johnson
After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.